2.53
+0.14(+5.86%)
Currency In USD
| Previous Close | 2.39 |
| Open | 2.38 |
| Day High | 2.59 |
| Day Low | 2.32 |
| 52-Week High | 39.45 |
| 52-Week Low | 2.08 |
| Volume | 97,979 |
| Average Volume | 31,855 |
| Market Cap | 10.52M |
| PE | -0.08 |
| EPS | -32.7 |
| Moving Average 50 Days | 3.01 |
| Moving Average 200 Days | 8.13 |
| Change | 0.14 |
If you invested $1000 in Eterna Therapeutics Inc. (ERNA) 10 years ago, it would be worth $0.32 as of June 18, 2025 at a share price of $2.53. Whereas If you bought $1000 worth of Eterna Therapeutics Inc. (ERNA) shares 5 years ago, it would be worth $1.52 as of June 18, 2025 at a share price of $2.53.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
GlobeNewswire Inc.
Jun 10, 2025 1:30 PM GMT
CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued and outsta
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025
GlobeNewswire Inc.
May 28, 2025 12:30 PM GMT
New data finds novel cell therapy successfully converts “cold” ovarian tumors into “hot,” demonstrating potential to unlock immune response and improve outcomesCAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), d
Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations
GlobeNewswire Inc.
May 14, 2025 12:30 PM GMT
New entity, ErnexaTX2, reflects progress toward clinical readinessCAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseas